Gilead’s revenue rises 17% driven by sales of coronavirus treatment remdesivir


A lab technician inspects filled vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California.

Gilead Sciences Inc | Reuters

Gilead Sciences reported stronger-than-expected third-quarter earnings on Wednesday as sales of its coronavirus treatment remdesivir touted by President Donald Trump drove revenue up by 17% from last year.

Gilead’s antiviral drug remdesivir, selling under the brand name Veklury, last week became the first and only treatment granted full approval by the U.S. Food and Drug Administration for treating Covid-19 patients. The coronavirus treatment generated $873 million in sales during the third quarter, mostly in the U.S., the company said.

Gilead’s total sales were $6.5 billion in the third quarter, up from $5.5 billion a year ago and more than the $6.3 billion analysts expected. The company reported adjusted earnings of $2.11 per share, higher than the $1.90 per share projected by analysts surveyed by Refinitiv.

Gilead also cut the top end of its full-year outlook, now expecting revenue between $23 billion and $23.5 billion. It had previously said it expected revenue between $23 billion and $25 billion.

Excluding remdesivir, the company’s total sales increased 2% to $5.6 billion compared with a year earlier. The California-based company said remdesivir’s revenue is “subject to significant volatility and uncertainly” depending on the global health environment.

Gilead said sales in its HIV drug business increased 8% to $4.5 billion during the third quarter. Sales for its HCV franchise fell 31% to $464 million as people in the U.S. and Europe had fewer health screenings due to the pandemic.

The company said in August that it planned to produce more than 2 million treatment courses of remdesivir by the end of the year and anticipated being able to make “several million more” in 2021.

“We’re… now in position to meet global demand because of the work we’ve done since January to ramp up our supply,” CEO Daniel O’Day said during an investor call on Wednesday.

Remdesivir costs $2,340 for a five-day treatment course for people covered by government health programs and other countries’ health-care systems, and $3,120 for U.S. patients with private health coverage.



Source link

Recent Articles

European markets head for higher open as investors look to reverse negative slide

LONDON — European stocks are expected to open higher on Wednesday as markets look to reverse a negative slide in the previous trading...

This new gaming laptop is a strange rival for your Steam Deck dollars

If you’re having trouble getting your hands on a Steam Deck, Chinese tech company GPD has a rather oddball solution It’s called the GPD...

Samsung set for bumper Q2 despite smartphone slump

Samsung is expected to post its best second quarter results for four years, despite its lack of immunity from the smartphone industry’s current...

Project Cambria is Meta’s most important VR headset right now

Meta seemingly has high hopes for Project Cambria, with a leaked internal memo saying that the upcoming VR headset is one of Meta’s...

AMD FSR 2.0 mods start to flood in as gamers can’t wait for frame rate boosts

AMD’s FSR 2.0 (FidelityFX Super Resolution) is still relatively fresh to the gaming scene, and hardly in any games at all yet – but...

Related Stories

Leave A Reply

Please enter your comment!
Please enter your name here

Stay on op - Ge the daily news in your inbox

[tdn_block_newsletter_subscribe input_placeholder=”Email address” btn_text=”Subscribe” tds_newsletter2-image=”730″ tds_newsletter2-image_bg_color=”#c3ecff” tds_newsletter3-input_bar_display=”” tds_newsletter4-image=”731″ tds_newsletter4-image_bg_color=”#fffbcf” tds_newsletter4-btn_bg_color=”#f3b700″ tds_newsletter4-check_accent=”#f3b700″ tds_newsletter5-tdicon=”tdc-font-fa tdc-font-fa-envelope-o” tds_newsletter5-btn_bg_color=”#000000″ tds_newsletter5-btn_bg_color_hover=”#4db2ec” tds_newsletter5-check_accent=”#000000″ tds_newsletter6-input_bar_display=”row” tds_newsletter6-btn_bg_color=”#da1414″ tds_newsletter6-check_accent=”#da1414″ tds_newsletter7-image=”732″ tds_newsletter7-btn_bg_color=”#1c69ad” tds_newsletter7-check_accent=”#1c69ad” tds_newsletter7-f_title_font_size=”20″ tds_newsletter7-f_title_font_line_height=”28px” tds_newsletter8-input_bar_display=”row” tds_newsletter8-btn_bg_color=”#00649e” tds_newsletter8-btn_bg_color_hover=”#21709e” tds_newsletter8-check_accent=”#00649e” embedded_form_code=”YWN0aW9uJTNEJTIybGlzdC1tYW5hZ2UuY29tJTJGc3Vic2NyaWJlJTIy” tds_newsletter=”tds_newsletter1″ tds_newsletter3-all_border_width=”2″ tds_newsletter3-all_border_color=”#e6e6e6″ tdc_css=”eyJhbGwiOnsibWFyZ2luLWJvdHRvbSI6IjAiLCJib3JkZXItY29sb3IiOiIjZTZlNmU2IiwiZGlzcGxheSI6IiJ9fQ==” tds_newsletter1-btn_bg_color=”#0d42a2″ tds_newsletter1-f_btn_font_family=”406″ tds_newsletter1-f_btn_font_transform=”uppercase” tds_newsletter1-f_btn_font_weight=”800″ tds_newsletter1-f_btn_font_spacing=”1″ tds_newsletter1-f_input_font_line_height=”eyJhbGwiOiIzIiwicG9ydHJhaXQiOiIyLjYiLCJsYW5kc2NhcGUiOiIyLjgifQ==” tds_newsletter1-f_input_font_family=”406″ tds_newsletter1-f_input_font_size=”eyJhbGwiOiIxMyIsImxhbmRzY2FwZSI6IjEyIiwicG9ydHJhaXQiOiIxMSIsInBob25lIjoiMTMifQ==” tds_newsletter1-input_bg_color=”#fcfcfc” tds_newsletter1-input_border_size=”0″ tds_newsletter1-f_btn_font_size=”eyJsYW5kc2NhcGUiOiIxMiIsInBvcnRyYWl0IjoiMTEiLCJhbGwiOiIxMyJ9″ content_align_horizontal=”content-horiz-center”]